[The world's first malaria vaccine: Hope and challenge]

Area of Science:

• Immunology
• Vaccinology
• Infectious Diseases

Background:

• Malaria remains a major global health threat, particularly to children in endemic regions.
• Plasmodium falciparum is the deadliest malaria parasite, necessitating effective interventions.
• The RTS,S/AS01 vaccine targets the pre-erythrocytic stage of malaria parasites.

Purpose of the Study:

• To evaluate the RTS,S/AS01 malaria vaccine's role in combating Plasmodium falciparum.
• To assess the vaccine's impact on childhood malaria mortality and morbidity.
• To position the RTS,S/AS01 vaccine within the broader context of malaria control and elimination efforts.

Main Methods:

• Over 30 years of research and development.
• Extensive clinical trials were conducted.
• WHO recommendation for deployment in high-endemic areas.

Main Results:

• RTS,S/AS01 vaccine recommended by WHO for children in high-risk areas.
• Offers approximately 30% protective efficacy against malaria.
• Requires a four-dose regimen and provides short-term immunity.

Conclusions:

• The RTS,S/AS01 vaccine represents a milestone in malaria control, expected to save numerous lives.
• Despite its limitations, the vaccine is crucial for reducing childhood malaria deaths and cases.
• Its success accelerates progress in developing other parasitic disease vaccines and a more effective malaria vaccine.